Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quidel

This article was originally published in The Gray Sheet

Executive Summary

Debt holder Amoco Technology Company converts a 7.9% note for $2.4 mil. plus $658,839 in interest into 428,532 shares of Quidel common stock at a $7.14 per share conversion price. The note was issued in 1990 and "would have become convertible at the option of Quidel in August of this year at the same conversion price," according to Quidel. The maker of rapid diagnostic tests announced the retirement of $4 mil. in 12% unsecured long-term debt earlier this month ("The Gray Sheet" July 19, p. 22). The firm says the two transactions increase shareholder equity by 72% over the March 31 level.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel